Mutational Analysis of the DOK2 Haploinsufficient Tumor Suppressor Gene in Chronic Myelomonocytic Leukemia (CMML)

Overview

Journal Leukemia

Specialties Hematology
Oncology

Date 2014 Sep 26

PMID 25252871

Citations 6

Authors

E Coppin

V Gelsi-Boyer

X Morelli

N Cervera

A Murati

P P Pandolfi

D Birnbaum

J A Nunes

Affiliations

Soon will be listed here.

Citing Articles

Chromosome-level Asian elephant genome assembly and comparative genomics of long-lived mammals reveal the common substitutions for cancer resistance.

Li X, Wang P, Pan Q, Liu G, Liu W, Omotoso O Aging Cell. 2023; 22(9):e13917.

PMID: 37395176 PMC: 10497851. DOI: 10.1111/acel.13917.

Introduction to DOK2 and its potential role in cancer.

Sun P, Li R, Meng Y, Xi S, Wang Q, Yang X Physiol Res. 2021; 70(5):671-685.

PMID: 34505522 PMC: 8820521. DOI: 10.33549/physiolres.934710.

Genomic analysis of a riboflavin-overproducing Ashbya gossypii mutant isolated by disparity mutagenesis.

Kato T, Azegami J, Yokomori A, Dohra H, El Enshasy H, Park E BMC Genomics. 2020; 21(1):319.

PMID: 32326906 PMC: 7181572. DOI: 10.1186/s12864-020-6709-7.

Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations.

Chang J, Tian J, Zhu Y, Zhong R, Zhai K, Li J Nat Commun. 2018; 9(1):3688.

PMID: 30206226 PMC: 6134090. DOI: 10.1038/s41467-018-06136-x.

Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.

Fang F, Cardenas H, Huang H, Jiang G, Perkins S, Zhang C Cancer Res. 2017; 78(3):631-644.

PMID: 29229600 PMC: 5811373. DOI: 10.1158/0008-5472.CAN-17-1492.

References

Yasuda T, Shirakata M, Iwama A, Ishii A, Ebihara Y, Osawa M . Role of Dok-1 and Dok-2 in myeloid homeostasis and suppression of leukemia. J Exp Med. 2004; 200(12):1681-7. PMC: 2211997. DOI: 10.1084/jem.20041247. View

Favre C, Gerard A, Clauzier E, Pontarotti P, Olive D, Nunes J . DOK4 and DOK5: new Dok-related genes expressed in human T cells. Genes Immun. 2003; 4(1):40-5. DOI: 10.1038/sj.gene.6363891. View

Guittard G, Gerard A, Dupuis-Coronas S, Tronchere H, Mortier E, Favre C . Cutting edge: Dok-1 and Dok-2 adaptor molecules are regulated by phosphatidylinositol 5-phosphate production in T cells. J Immunol. 2009; 182(7):3974-8. DOI: 10.4049/jimmunol.0804172. View

Gelsi-Boyer V, Cervera N, Bertucci F, Trouplin V, Remy V, Olschwang S . Gene expression profiling separates chronic myelomonocytic leukemia in two molecular subtypes. Leukemia. 2007; 21(11):2359-62. DOI: 10.1038/sj.leu.2404805. View

Tefferi A . Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010; 24(6):1128-38. PMC: 3035972. DOI: 10.1038/leu.2010.69. View

Niki M, Di Cristofano A, Zhao M, Honda H, Hirai H, Van Aelst L . Role of Dok-1 and Dok-2 in leukemia suppression. J Exp Med. 2004; 200(12):1689-95. PMC: 2211998. DOI: 10.1084/jem.20041306. View

Mihrshahi R, Brown M . Downstream of tyrosine kinase 1 and 2 play opposing roles in CD200 receptor signaling. J Immunol. 2010; 185(12):7216-22. PMC: 2999833. DOI: 10.4049/jimmunol.1002858. View

An C, Kim M, Yoo N, Lee S . Mutational and expressional analysis of a haploinsufficient tumor suppressor gene DOK2 in gastric and colorectal cancers. APMIS. 2011; 119(8):562-4. DOI: 10.1111/j.1600-0463.2011.02749.x. View

Berger A, Niki M, Morotti A, Taylor B, Socci N, Viale A . Identification of DOK genes as lung tumor suppressors. Nat Genet. 2010; 42(3):216-23. PMC: 2956443. DOI: 10.1038/ng.527. View

10.

Orazi A, Germing U . The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia. 2008; 22(7):1308-19. DOI: 10.1038/leu.2008.119. View

11.

Vardiman J, Thiele J, Arber D, Brunning R, Borowitz M, Porwit A . The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009; 114(5):937-51. DOI: 10.1182/blood-2009-03-209262. View

12.

Boulay I, Nemorin J, Duplay P . Phosphotyrosine binding-mediated oligomerization of downstream of tyrosine kinase (Dok)-1 and Dok-2 is involved in CD2-induced Dok phosphorylation. J Immunol. 2005; 175(7):4483-9. DOI: 10.4049/jimmunol.175.7.4483. View

13.

Suzu S, Nomaguchi K, Yamada M, Hayasawa H, Kimura F, Motoyoshi K . p56(dok-2) as a cytokine-inducible inhibitor of cell proliferation and signal transduction. EMBO J. 2000; 19(19):5114-22. PMC: 302098. DOI: 10.1093/emboj/19.19.5114. View

14.

Kim M, Chung N, Yoo N, Lee S . Mutational analysis of DOK2 tumor suppressor gene in acute leukemias. Leuk Res. 2011; 35(6):e87-8. DOI: 10.1016/j.leukres.2011.01.027. View

15.

Mashima R, Hishida Y, Tezuka T, Yamanashi Y . The roles of Dok family adapters in immunoreceptor signaling. Immunol Rev. 2009; 232(1):273-85. DOI: 10.1111/j.1600-065X.2009.00844.x. View